Potential clinical biomarkers in rheumatoid arthritis with an omic approach
ABSTRACT: Objective: To aid in the selection of the most suitable therapeutic option in patients with diagnosis of rheumatoid arthritis according to the phase of disease, through the review of articles that identify omics biological markers. Methods: A systematic review in PubMed/Medline databases w...
- Autores:
-
Puentes Osorio, Yolima
Amariles Muñoz, Pedro
Díaz Coronado, Juan Camilo
Calleja, Miguel Ángel
Merino, Vicente
Taborda, Daniel
- Tipo de recurso:
- Review article
- Fecha de publicación:
- 2021
- Institución:
- Universidad de Antioquia
- Repositorio:
- Repositorio UdeA
- Idioma:
- eng
- OAI Identifier:
- oai:bibliotecadigital.udea.edu.co:10495/40330
- Acceso en línea:
- https://hdl.handle.net/10495/40330
- Palabra clave:
- Artritis Reumatoide
Arthritis, Rheumatoid
Genómica
Genomics
Proteómica
Proteomics
Terapéutica
Therapeutics
Biomarcadores
Biomarkers
Farmacogenética
Pharmacogenetics
Metabolómica
Metabolomics
Polimorfismo Genético
Polymorphism, Genetic
https://id.nlm.nih.gov/mesh/D001172
https://id.nlm.nih.gov/mesh/D023281
https://id.nlm.nih.gov/mesh/D040901
https://id.nlm.nih.gov/mesh/D013812
https://id.nlm.nih.gov/mesh/D015415
https://id.nlm.nih.gov/mesh/D010597
https://id.nlm.nih.gov/mesh/D055432
https://id.nlm.nih.gov/mesh/D011110
- Rights
- openAccess
- License
- https://creativecommons.org/licenses/by/4.0/
| id |
UDEA2_f2310fe6b4d5f4ba7207ff10a14ebf47 |
|---|---|
| oai_identifier_str |
oai:bibliotecadigital.udea.edu.co:10495/40330 |
| network_acronym_str |
UDEA2 |
| network_name_str |
Repositorio UdeA |
| repository_id_str |
|
| dc.title.spa.fl_str_mv |
Potential clinical biomarkers in rheumatoid arthritis with an omic approach |
| title |
Potential clinical biomarkers in rheumatoid arthritis with an omic approach |
| spellingShingle |
Potential clinical biomarkers in rheumatoid arthritis with an omic approach Artritis Reumatoide Arthritis, Rheumatoid Genómica Genomics Proteómica Proteomics Terapéutica Therapeutics Biomarcadores Biomarkers Farmacogenética Pharmacogenetics Metabolómica Metabolomics Polimorfismo Genético Polymorphism, Genetic https://id.nlm.nih.gov/mesh/D001172 https://id.nlm.nih.gov/mesh/D023281 https://id.nlm.nih.gov/mesh/D040901 https://id.nlm.nih.gov/mesh/D013812 https://id.nlm.nih.gov/mesh/D015415 https://id.nlm.nih.gov/mesh/D010597 https://id.nlm.nih.gov/mesh/D055432 https://id.nlm.nih.gov/mesh/D011110 |
| title_short |
Potential clinical biomarkers in rheumatoid arthritis with an omic approach |
| title_full |
Potential clinical biomarkers in rheumatoid arthritis with an omic approach |
| title_fullStr |
Potential clinical biomarkers in rheumatoid arthritis with an omic approach |
| title_full_unstemmed |
Potential clinical biomarkers in rheumatoid arthritis with an omic approach |
| title_sort |
Potential clinical biomarkers in rheumatoid arthritis with an omic approach |
| dc.creator.fl_str_mv |
Puentes Osorio, Yolima Amariles Muñoz, Pedro Díaz Coronado, Juan Camilo Calleja, Miguel Ángel Merino, Vicente Taborda, Daniel |
| dc.contributor.author.none.fl_str_mv |
Puentes Osorio, Yolima Amariles Muñoz, Pedro Díaz Coronado, Juan Camilo Calleja, Miguel Ángel Merino, Vicente Taborda, Daniel |
| dc.contributor.researchgroup.spa.fl_str_mv |
Promoción y Prevención Farmacéutica |
| dc.subject.decs.none.fl_str_mv |
Artritis Reumatoide Arthritis, Rheumatoid Genómica Genomics Proteómica Proteomics Terapéutica Therapeutics Biomarcadores Biomarkers Farmacogenética Pharmacogenetics Metabolómica Metabolomics Polimorfismo Genético Polymorphism, Genetic |
| topic |
Artritis Reumatoide Arthritis, Rheumatoid Genómica Genomics Proteómica Proteomics Terapéutica Therapeutics Biomarcadores Biomarkers Farmacogenética Pharmacogenetics Metabolómica Metabolomics Polimorfismo Genético Polymorphism, Genetic https://id.nlm.nih.gov/mesh/D001172 https://id.nlm.nih.gov/mesh/D023281 https://id.nlm.nih.gov/mesh/D040901 https://id.nlm.nih.gov/mesh/D013812 https://id.nlm.nih.gov/mesh/D015415 https://id.nlm.nih.gov/mesh/D010597 https://id.nlm.nih.gov/mesh/D055432 https://id.nlm.nih.gov/mesh/D011110 |
| dc.subject.meshuri.none.fl_str_mv |
https://id.nlm.nih.gov/mesh/D001172 https://id.nlm.nih.gov/mesh/D023281 https://id.nlm.nih.gov/mesh/D040901 https://id.nlm.nih.gov/mesh/D013812 https://id.nlm.nih.gov/mesh/D015415 https://id.nlm.nih.gov/mesh/D010597 https://id.nlm.nih.gov/mesh/D055432 https://id.nlm.nih.gov/mesh/D011110 |
| description |
ABSTRACT: Objective: To aid in the selection of the most suitable therapeutic option in patients with diagnosis of rheumatoid arthritis according to the phase of disease, through the review of articles that identify omics biological markers. Methods: A systematic review in PubMed/Medline databases was performed. We searched articles from August 2014 to September 2019, in English and Spanish, filtered by title and full text; and using the terms "Biomarkers" AND “Rheumatoid arthritis". Results: This article supplies an exhaustive review from research of objective measurement, omics biomarkers and how disease activity appraise decrease unpredictability in treatment determinations, and finally, economic, and clinical outcomes of treatment options by biomarkers’ potential influence. A total of 122 articles were included. Only 92 met the established criteria for review purposes and 17 relevant references about the topic were included as well. Therefore, it was possible to identify 196 potential clinical biomarkers: 22 non-omics, 20 epigenomics, 33 genomics, 21 transcriptomics, 78 proteomics, 4 glycomics, 1 lipidomics and 17 metabolomics. Conclusion: A biomarker is a measurable indicator of some, biochemical, physiological, or morphological condition; evaluable at a molecular, biochemical, or cellular level. Biomarkers work as indicators of physiological or pathological processes, or as a result of a therapeutic management. In the last fve years, new biomarkers have been identified, especially the omics, which are those that proceed from the investigation of genes (genomics), metabolites (metabolomics), and proteins (proteomics). These biomarkers contribute to the physician choosing the best therapeutic option in patients with rheumatoid arthritis. |
| publishDate |
2021 |
| dc.date.issued.none.fl_str_mv |
2021 |
| dc.date.accessioned.none.fl_str_mv |
2024-06-26T20:48:17Z |
| dc.date.available.none.fl_str_mv |
2024-06-26T20:48:17Z |
| dc.type.spa.fl_str_mv |
Artículo de revisión |
| dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_2df8fbb1 |
| dc.type.coar.spa.fl_str_mv |
http://purl.org/coar/resource_type/c_dcae04bc |
| dc.type.redcol.spa.fl_str_mv |
https://purl.org/redcol/resource_type/ARTREV |
| dc.type.coarversion.spa.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.driver.spa.fl_str_mv |
info:eu-repo/semantics/article |
| dc.type.version.spa.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| format |
http://purl.org/coar/resource_type/c_dcae04bc |
| status_str |
publishedVersion |
| dc.identifier.citation.spa.fl_str_mv |
Puentes-Osorio, Y., Amariles, P., Calleja, M.Á. et al. Potential clinical biomarkers in rheumatoid arthritis with an omic approach. Autoimmun Highlights 12, 9 (2021). https://doi.org/10.1186/s13317-021-00152-6 |
| dc.identifier.issn.none.fl_str_mv |
2038-0305 |
| dc.identifier.uri.none.fl_str_mv |
https://hdl.handle.net/10495/40330 |
| dc.identifier.doi.none.fl_str_mv |
10.1186/s13317-021-00152-6 |
| dc.identifier.eissn.none.fl_str_mv |
2038-3274 |
| identifier_str_mv |
Puentes-Osorio, Y., Amariles, P., Calleja, M.Á. et al. Potential clinical biomarkers in rheumatoid arthritis with an omic approach. Autoimmun Highlights 12, 9 (2021). https://doi.org/10.1186/s13317-021-00152-6 2038-0305 10.1186/s13317-021-00152-6 2038-3274 |
| url |
https://hdl.handle.net/10495/40330 |
| dc.language.iso.spa.fl_str_mv |
eng |
| language |
eng |
| dc.relation.ispartofjournalabbrev.spa.fl_str_mv |
Auto. Immun. Highlights. |
| dc.relation.citationendpage.spa.fl_str_mv |
21 |
| dc.relation.citationissue.spa.fl_str_mv |
9 |
| dc.relation.citationstartpage.spa.fl_str_mv |
1 |
| dc.relation.citationvolume.spa.fl_str_mv |
12 |
| dc.relation.ispartofjournal.spa.fl_str_mv |
Autoimmunity Highlights |
| dc.rights.uri.spa.fl_str_mv |
https://creativecommons.org/licenses/by/4.0/ |
| dc.rights.uri.*.fl_str_mv |
http://creativecommons.org/licenses/by/2.5/co/ |
| dc.rights.accessrights.spa.fl_str_mv |
info:eu-repo/semantics/openAccess |
| dc.rights.coar.spa.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
| rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0/ http://creativecommons.org/licenses/by/2.5/co/ http://purl.org/coar/access_right/c_abf2 |
| eu_rights_str_mv |
openAccess |
| dc.format.extent.spa.fl_str_mv |
21 páginas |
| dc.format.mimetype.spa.fl_str_mv |
application/pdf |
| dc.publisher.spa.fl_str_mv |
BMC (BioMed Central) |
| dc.publisher.place.spa.fl_str_mv |
Londres, Inglaterra |
| institution |
Universidad de Antioquia |
| bitstream.url.fl_str_mv |
https://bibliotecadigital.udea.edu.co/bitstreams/5ff265f9-4cce-4ecc-bd15-bbe25efbb8e2/download https://bibliotecadigital.udea.edu.co/bitstreams/16f163c2-6ebf-4c9e-9775-866a1bbfca8e/download https://bibliotecadigital.udea.edu.co/bitstreams/8918b44f-50aa-40ff-835a-5e685cb9b0f6/download https://bibliotecadigital.udea.edu.co/bitstreams/1ee1bd9f-9749-4554-bc6d-5011f58dfea9/download https://bibliotecadigital.udea.edu.co/bitstreams/edb317a1-40a5-4bd6-89f3-8d1e29e9138e/download |
| bitstream.checksum.fl_str_mv |
57a9d4e950e376792769347ad939ffe0 1646d1f6b96dbbbc38035efc9239ac9c 8a4605be74aa9ea9d79846c1fba20a33 958a59a763a557fd83551cb80e859e8d 2cd988712b17762bf2157b5b823f715c |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio Institucional de la Universidad de Antioquia |
| repository.mail.fl_str_mv |
aplicacionbibliotecadigitalbiblioteca@udea.edu.co |
| _version_ |
1851052614801686528 |
| spelling |
Puentes Osorio, YolimaAmariles Muñoz, PedroDíaz Coronado, Juan CamiloCalleja, Miguel ÁngelMerino, VicenteTaborda, DanielPromoción y Prevención Farmacéutica2024-06-26T20:48:17Z2024-06-26T20:48:17Z2021Puentes-Osorio, Y., Amariles, P., Calleja, M.Á. et al. Potential clinical biomarkers in rheumatoid arthritis with an omic approach. Autoimmun Highlights 12, 9 (2021). https://doi.org/10.1186/s13317-021-00152-62038-0305https://hdl.handle.net/10495/4033010.1186/s13317-021-00152-62038-3274ABSTRACT: Objective: To aid in the selection of the most suitable therapeutic option in patients with diagnosis of rheumatoid arthritis according to the phase of disease, through the review of articles that identify omics biological markers. Methods: A systematic review in PubMed/Medline databases was performed. We searched articles from August 2014 to September 2019, in English and Spanish, filtered by title and full text; and using the terms "Biomarkers" AND “Rheumatoid arthritis". Results: This article supplies an exhaustive review from research of objective measurement, omics biomarkers and how disease activity appraise decrease unpredictability in treatment determinations, and finally, economic, and clinical outcomes of treatment options by biomarkers’ potential influence. A total of 122 articles were included. Only 92 met the established criteria for review purposes and 17 relevant references about the topic were included as well. Therefore, it was possible to identify 196 potential clinical biomarkers: 22 non-omics, 20 epigenomics, 33 genomics, 21 transcriptomics, 78 proteomics, 4 glycomics, 1 lipidomics and 17 metabolomics. Conclusion: A biomarker is a measurable indicator of some, biochemical, physiological, or morphological condition; evaluable at a molecular, biochemical, or cellular level. Biomarkers work as indicators of physiological or pathological processes, or as a result of a therapeutic management. In the last fve years, new biomarkers have been identified, especially the omics, which are those that proceed from the investigation of genes (genomics), metabolites (metabolomics), and proteins (proteomics). These biomarkers contribute to the physician choosing the best therapeutic option in patients with rheumatoid arthritis.COL007466121 páginasapplication/pdfengBMC (BioMed Central)Londres, Inglaterrahttps://creativecommons.org/licenses/by/4.0/http://creativecommons.org/licenses/by/2.5/co/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2Potential clinical biomarkers in rheumatoid arthritis with an omic approachArtículo de revisiónhttp://purl.org/coar/resource_type/c_dcae04bchttp://purl.org/coar/resource_type/c_2df8fbb1https://purl.org/redcol/resource_type/ARTREVhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArtritis ReumatoideArthritis, RheumatoidGenómicaGenomicsProteómicaProteomicsTerapéuticaTherapeuticsBiomarcadoresBiomarkersFarmacogenéticaPharmacogeneticsMetabolómicaMetabolomicsPolimorfismo GenéticoPolymorphism, Genetichttps://id.nlm.nih.gov/mesh/D001172https://id.nlm.nih.gov/mesh/D023281https://id.nlm.nih.gov/mesh/D040901https://id.nlm.nih.gov/mesh/D013812https://id.nlm.nih.gov/mesh/D015415https://id.nlm.nih.gov/mesh/D010597https://id.nlm.nih.gov/mesh/D055432https://id.nlm.nih.gov/mesh/D011110Auto. Immun. Highlights.219112Autoimmunity HighlightsPublicationORIGINALPuentesYolima_2021_Potential_Clinical_Biomarkers.pdfPuentesYolima_2021_Potential_Clinical_Biomarkers.pdfArtículo de revisiónapplication/pdf1645867https://bibliotecadigital.udea.edu.co/bitstreams/5ff265f9-4cce-4ecc-bd15-bbe25efbb8e2/download57a9d4e950e376792769347ad939ffe0MD51trueAnonymousREADCC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8927https://bibliotecadigital.udea.edu.co/bitstreams/16f163c2-6ebf-4c9e-9775-866a1bbfca8e/download1646d1f6b96dbbbc38035efc9239ac9cMD52falseAnonymousREADLICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://bibliotecadigital.udea.edu.co/bitstreams/8918b44f-50aa-40ff-835a-5e685cb9b0f6/download8a4605be74aa9ea9d79846c1fba20a33MD53falseAnonymousREADTEXTPuentesYolima_2021_Potential_Clinical_Biomarkers.pdf.txtPuentesYolima_2021_Potential_Clinical_Biomarkers.pdf.txtExtracted texttext/plain101741https://bibliotecadigital.udea.edu.co/bitstreams/1ee1bd9f-9749-4554-bc6d-5011f58dfea9/download958a59a763a557fd83551cb80e859e8dMD54falseAnonymousREADTHUMBNAILPuentesYolima_2021_Potential_Clinical_Biomarkers.pdf.jpgPuentesYolima_2021_Potential_Clinical_Biomarkers.pdf.jpgGenerated Thumbnailimage/jpeg13608https://bibliotecadigital.udea.edu.co/bitstreams/edb317a1-40a5-4bd6-89f3-8d1e29e9138e/download2cd988712b17762bf2157b5b823f715cMD55falseAnonymousREAD10495/40330oai:bibliotecadigital.udea.edu.co:10495/403302025-03-27 01:06:09.78https://creativecommons.org/licenses/by/4.0/open.accesshttps://bibliotecadigital.udea.edu.coRepositorio Institucional de la Universidad de Antioquiaaplicacionbibliotecadigitalbiblioteca@udea.edu.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 |
